Background: Nocturia is one of the commonest nonmotor symptoms in Parkinson's disease (PD) and has a significant impact on quality of life both for patients and their carers. There exists a relation between nocturia and poor sleep quality, falls, and institutionalization. Nocturia may manifest as a result of reduced functional bladder capacity or nocturnal polyuria; however, most often the cause is multifactorial. Disorders of circadian rhythm regulation are known to occur with sleep disturbances in PD may also contribute to nocturia.
Methods And Results: In this review, an overview of the assessment and management of nocturia in patients with PD is presented. History taking, medication review, and a bladder diary form the cornerstone of the evaluation. Urinalysis, ultrasonography, and urodynamic studies help to assess the cause for lower urinary tract symptoms and exclude concomitant pathologies, such as bladder outlet obstruction. Antimuscarinic medications are the first-line treatment for the overactive bladder; however, caution is needed when using these medications in individuals predisposed to cognitive impairment. Desmopressin is effective for managing nocturnal polyuria.
Conclusions: An individualized approach is recommended to optimize the management of nocturia in PD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178648 | PMC |
| http://dx.doi.org/10.1002/mdc3.12374 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Vivo UV-Induced Fluorescence Spectroscopy of Skin in Parkinson's Disease.
Dokl Biol Sci
January 2025
Research Center of Neurology, Moscow, Russia.
Characteristic patterns of UV-induced skin autofluorescence were determined for patients with Parkinson's disease (PD) and associated with dysmetabolic alterations, such as nonenzymatic protein glycation, an increase in extracellular matrix stiffness, impaired metabolism of tissue fluorophores, mitochondrial dysfunction, and accumulation of aberrant proteins. Key differences in skin autofluorescence spectra were for the first time observed in PD, making it possible to discriminate between PD patients and healthy persons or individuals without signs of chronic neurodegeneration. Namely, skin fluorescence related to the reflected signal upon excitation with UV light at 375 nm was lower in PD patients.
View Article and Find Full Text PDFParkinson's disease and deep brain stimulation of the subthalamic nucleus (STN-DBS): long-term disease evaluation and neuropsychological outcomes in a 9-year matched-controlled study.
Neurosurg Rev
January 2025
Department of Neurosurgery, Hospital Universitario Fundación Jiménez Díaz, Av. De los Reyes Católicos, 2, Madrid, 28040, Spain.
Matched-controlled long-term disease evaluation and neuropsychological outcomes derived from deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson´s disease (PD) are lacking, with inconsistent results regarding the cognitive impact of this procedure. Here we study the long-term effects associated to DBS comparing outcomes with a matched control group. A prospective observational study of 40 patients with PD with bilateral STN-DBS, with a mean follow-up of 9 (6-12) years was conducted.
View Article and Find Full Text PDFManganese exposure induces parkinsonism-like symptoms by Serpina3n-TFEB-v/p-ATPase signaling mediated lysosomal dysfunction.
Cell Biol Toxicol
January 2025
Department of Environmental Medicine, School of Medicine, Chongqing University, Chongqing, China.
Manganese (Mn) is a neurotoxin that has been etiologically linked to the development of neurodegenerative diseases in the case of overexposure. It is widely accepted that overexposure to Mn leads to manganism, which has clinical symptoms similar to Parkinson's disease (PD), and is referred to as parkinsonism. Astrocytes have been reported to scavenge and degrade extracellular α-synuclein (α-Syn) in the brain.
View Article and Find Full Text PDFImpact of diabetes mellitus type two on incidence and progression of Parkinson's disease: a systematic review of longitudinal patient cohorts.
J Neural Transm (Vienna)
January 2025
Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
Parkinson's disease (PD) is a chronic neurodegenerative disease of the elderly. Patients suffer from progressive motor and non-motor symptoms. Further, PD patients often present geriatric features like multimorbidity and polypharmacotherapy.
View Article and Find Full Text PDFA PARK7 Mutation-Induced Early-Onset Parkinson's Disease in a Moroccan Family: Expanding the Geographic Spectrum.
Mov Disord Clin Pract
January 2025
Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Hôpital de la Salpêtrière, INSERM, CNRS, Paris, France.
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and nonmotor symptoms, with a significant genetic component. Early-onset Parkinson's disease (EOPD), manifesting before age 45, is often linked to mutations in genes such as PARK2, PINK1, and PARK7, the latter coding for the protein DJ-1.
Objective: We present the first reported cases of EOPD carrying a previously undescribed homozygous PARK7 mutation, p.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!